<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106028</url>
  </required_header>
  <id_info>
    <org_study_id>2003100</org_study_id>
    <secondary_id>HMR4003I/3001</secondary_id>
    <nct_id>NCT00106028</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children</brief_title>
  <official_title>Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with Osteogenesis Imperfecta (OI) have bone pain, low bone mass and fractures. There
      are no approved drugs for the treatment of OI in children, even though some intravenous (IV)
      bisphosphonates are used off-label in some countries. In a single dose, pharmacokinetic
      study, data showed that risedronate was well tolerated in 28 children with OI. This three
      year study will test the safety and efficacy of risedronate in the treatment of children with
      OI. For the first year, patients will be randomized to the risedronate and placebo groups in
      a 2:1 ratio. For the second and third years of the study, all patients will receive
      risedronate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader. Duplicate scans obtained at screening and Month 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body BMD at Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body BMD at Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body BMD at Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body BMC at Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body BMC at Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body BMC at Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Z-score - Percent Change From Baseline to Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Z-score - Percent Change From Baseline to Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Z-score - Percent Change From Baseline to Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Z-score- Percent Change From Baseline to Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Z-score- Percent Change From Baseline to Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Z-score- Percent Change From Baseline to Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Area at Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Measured by DXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Area at Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Measured by DXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Area at Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Measured by DXA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body Bone Area Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body Bone Area Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body Bone Area Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Morphometric Vertebral Fracture at Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Morphometric Vertebral Fracture measured by semi-quantitative (SQ) analysis of x-rays using the Genant scoring system at endpoint. (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). New fracture = SQ score is 0 at baseline and &gt;0 at the specified end visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Morphometric Vertebral Fracture at Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Morphometric Vertebral Fracture measured by SQ analysis of x-rays using the Genant scoring system. (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). New fracture = SQ score is 0 at baseline and &gt;0 at the specified end visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorization by Number of New Morphometric Vertebral Fracture at Month 12, ITT</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Patients with 1 or more New Morphometric Vertebral Fracture as measured by SQ analysis of x-rays using the Genant scoring system (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). Incidence = SQ score is 0 at baseline and &gt;0 at post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorization by Number of New Morphometric Vertebral Fracture at Month 36, ITT</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Patients with 1 or more New Morphometric Vertebral Fracture as measured by SQ analysis of x-rays using the Genant scoring system (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). Incidence = SQ score is 0 at baseline and &gt;0 at post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence New Vertebral Fractures by SQ (Semi-Quantitative) Score, Patients Aged 4-9 Years, Month 12, ITT Population</measure>
    <time_frame>Month 12</time_frame>
    <description>Patients aged 4-9 years with new morphometric vertebral fractures as measured by SQ analysis of x-rays using the Genant scoring system at Month 12 +/- 14 days. (Ref: Genant 1993). SQ Score mild - 0/no fracture to Grade 1, Moderate to Severe - change from 0/no fracture to Grade 2-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence New Vertebral Fractures by SQ Score, Patients Aged 10-15 Years, Month 12, ITT Population</measure>
    <time_frame>Month 12</time_frame>
    <description>Patients aged 10-15 years with new morphometric vertebral fractures as measured by SQ analysis of x-rays using the Genant scoring system at Month 12 +/- 14 days. (Ref: Genant 1993). SQ Score mild - 0/no fracture to Grade 1, Moderate to Severe - change from 0/no fracture to Grade 2-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of Fracture in 12 Months (Kaplan-Meier Cumulative Incidence), ITT Population</measure>
    <time_frame>Time to First Event (days) up to 12 Months</time_frame>
    <description>Long bones include radius, ulna, humerus, tibia, fibula, femur, upper limb and lower limb fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinical Fractures, Month 12, ITT Population</measure>
    <time_frame>12 Months</time_frame>
    <description>Long bones include radius, ulna, humerus, tibia, fibula, femur, upper limb and lower limb fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BAP - Percent Change From Baseline to Month 12, ITT Population</measure>
    <time_frame>Baseline and 12 Months</time_frame>
    <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BAP - Percent Change From Baseline to Month 24, ITT Population</measure>
    <time_frame>Baseline and 24 Months</time_frame>
    <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BAP - Percent Change From Baseline to Month 36, ITT Population</measure>
    <time_frame>Baseline and 36 Months</time_frame>
    <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine NTX/Cr - Percent Change From Baseline at Month 12, ITT Population</measure>
    <time_frame>Baseline and Endpoint / Month 12</time_frame>
    <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine NTX/Cr - Percent Change From Baseline at Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine NTX/Cr - Percent Change From Baseline at Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wong-Baker FACES Pain Rating Scale - Change From Baseline to Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Wong-Baker FACES Pain Rating Scale (pain assessment scale using facial expressions, translated into a range from 0= no pain [smiling face] to 10= worst pain possible [distorted face with tears]; negative values indicate decrease in pain). Reference: Wong DL et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Age (Years), Change From Baseline to Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Age (Years), Change From Baseline to Month 24, ITT Population</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Age (Years), Change From Baseline to Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Growth Velocity - Change From Baseline to Month 12, ITT Population</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Annualized Growth Velocity [= bone age change from baseline x (365.25/time in days between baseline and the bone age measurement)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Growth Velocity - Change From Baseline to Month 36, ITT Population</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Annualized Growth Velocity [= bone age change from baseline x (365.25/time in days between baseline and the bone age measurement)]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Placebo Daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate sodium (Actonel)</intervention_name>
    <description>risedronate tablet once a day for one year followed by risedronate once a day for two years</description>
    <arm_group_label>Risedronate Daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet once a day for one year followed by risedronate once a day for two years</description>
    <arm_group_label>Placebo Daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  OI diagnosis

          -  increased risk of fracture: either has a history of at least 1 radiographically
             confirmed, non-traumatic or low impact fracture plus low bone mineral density (BMD) or
             has very low BMD with or without a history of fractures.

        Exclusion Criteria:

          -  Any bisphosphonate use within one year of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietrich H Wenderoth, MD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center, Children's Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State University BioMedical Imaging Laboratory and Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteocentrum, II. Interní klinika, Fakultní nemocnice Plzeň-Bory</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Children and Adolescents</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum und Poliklinik für Kinderheilkunde der Universität zu Köln</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Department of Pediatrics, Semmelwies University, Faculty of Medicine</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologic Rehabilitation Unit of the University of Verona</name>
      <address>
        <city>Valeggio sul Mincio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaklad Biochemii i Medycyny Doswiadczalnej (Biochemisty Dept, Institute &quot;Monument-Children Health Centre&quot;</name>
      <address>
        <city>Warzawa-Międzylesie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Company of Mary Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children,</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S210 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2005</study_first_submitted>
  <study_first_submitted_qc>March 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2005</study_first_posted>
  <results_first_submitted>April 15, 2009</results_first_submitted>
  <results_first_submitted_qc>May 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2010</results_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary disease: Osteogenesis Imperfecta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>147 children &gt; or = 4 and &lt; 16 years of age with Osteogenesis Imperfecta (OI) enrolled at 20 North American and international study centers starting 16NOV2004. Patients weighing 10-30 kg received risedronate 2.5 mg or placebo daily and patients weighing more than 30 kg received risedronate 5 mg or placebo daily.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Daily</title>
          <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
        </group>
        <group group_id="P2">
          <title>Risedronate Daily</title>
          <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49">ITT Population: Patients Randomized and Received at least 1 Dose of Study Drug</participants>
                <participants group_id="P2" count="94">ITT Population: Patients Randomized and Received at least 1 Dose of Study Drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 12 Completed/Started Open Label</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43">Completed Month 36</participants>
                <participants group_id="P2" count="82">Completed Month 36</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Daily</title>
          <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
        </group>
        <group group_id="B2">
          <title>Risedronate Daily</title>
          <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="143"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>There were 147 children enrolled in the study (stated in the protocol). However, 4 children were randomized but did not receive a dose of the study drug. Therefore, only 143 received at least 1 dose of study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="143.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="3.1"/>
                    <measurement group_id="B2" value="8.9" spread="3.4"/>
                    <measurement group_id="B3" value="8.825" spread="3.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 24, ITT Population</title>
        <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 24, ITT Population</title>
          <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.316" lower_limit="17.357" upper_limit="25.275"/>
                    <measurement group_id="O2" value="25.754" lower_limit="22.860" upper_limit="28.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0625</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.438</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.235</ci_lower_limit>
            <ci_upper_limit>9.111</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 36, ITT Population</title>
        <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 36, ITT Population</title>
          <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.216" lower_limit="28.191" upper_limit="38.241"/>
                    <measurement group_id="O2" value="34.753" lower_limit="31.076" upper_limit="38.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6103</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.537</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.424</ci_lower_limit>
            <ci_upper_limit>7.497</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body BMD at Month 12, ITT Population</title>
        <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body BMD at Month 12, ITT Population</title>
          <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.252" lower_limit="2.762" upper_limit="5.743"/>
                    <measurement group_id="O2" value="5.806" lower_limit="4.740" upper_limit="6.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0808</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and with fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.554</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.193</ci_lower_limit>
            <ci_upper_limit>3.301</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body BMD at Month 24, ITT Population</title>
        <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body BMD at Month 24, ITT Population</title>
          <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.716" lower_limit="7.897" upper_limit="11.535"/>
                    <measurement group_id="O2" value="10.214" lower_limit="8.899" upper_limit="11.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6466</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and with fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.498</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.648</ci_lower_limit>
            <ci_upper_limit>2.644</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body BMD at Month 36, ITT Population</title>
        <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body BMD at Month 36, ITT Population</title>
          <description>Percent Change from baseline in Total Body Bone Mineral Density (BMD) measured by DXA.</description>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.540" lower_limit="11.204" upper_limit="15.876"/>
                    <measurement group_id="O2" value="13.076" lower_limit="11.374" upper_limit="14.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7391</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and with fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.465</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.224</ci_lower_limit>
            <ci_upper_limit>2.294</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 12, ITT Population</title>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 12, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.885" lower_limit="13.645" upper_limit="22.124"/>
                    <measurement group_id="O2" value="28.218" lower_limit="25.038" upper_limit="31.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>LS Means and p-value are from ANCOVA model adjusted by baseline and with fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.333</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.258</ci_lower_limit>
            <ci_upper_limit>15.408</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 24, ITT Population</title>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 24, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.367" lower_limit="34.871" upper_limit="49.863"/>
                    <measurement group_id="O2" value="48.407" lower_limit="42.921" upper_limit="53.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>01789</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.807</ci_lower_limit>
            <ci_upper_limit>14.887</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 36, ITT Population</title>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 36, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.054" lower_limit="57.564" upper_limit="78.544"/>
                    <measurement group_id="O2" value="68.333" lower_limit="60.607" upper_limit="76.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9646</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.280</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.196</ci_lower_limit>
            <ci_upper_limit>12.755</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body BMC at Month 12, ITT Population</title>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body BMC at Month 12, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.483" lower_limit="13.395" upper_limit="19.570"/>
                    <measurement group_id="O2" value="21.977" lower_limit="19.772" upper_limit="24.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.494</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.912</ci_lower_limit>
            <ci_upper_limit>9.077</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body BMC at Month 24, ITT Population</title>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body BMC at Month 24, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.465" lower_limit="31.582" upper_limit="41.347"/>
                    <measurement group_id="O2" value="37.938" lower_limit="34.406" upper_limit="41.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6106</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.473</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.245</ci_lower_limit>
            <ci_upper_limit>7.192</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body BMC at Month 36, ITT Population</title>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body BMC at Month 36, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.211" lower_limit="49.470" upper_limit="62.952"/>
                    <measurement group_id="O2" value="56.526" lower_limit="51.549" upper_limit="61.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9372</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.315</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.598</ci_lower_limit>
            <ci_upper_limit>8.229</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Z-score - Percent Change From Baseline to Month 12, ITT Population</title>
        <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Z-score - Percent Change From Baseline to Month 12, ITT Population</title>
          <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
          <population>ITT Population</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.028" lower_limit="-14.899" upper_limit="2.844"/>
                    <measurement group_id="O2" value="25.648" lower_limit="18.993" upper_limit="32.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted for baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>31.675</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>21.051</ci_lower_limit>
            <ci_upper_limit>42.300</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Z-score - Percent Change From Baseline to Month 24, ITT Population</title>
        <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Z-score - Percent Change From Baseline to Month 24, ITT Population</title>
          <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
          <population>ITT Population</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.608" lower_limit="2.327" upper_limit="28.889"/>
                    <measurement group_id="O2" value="29.637" lower_limit="19.911" upper_limit="39.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0793</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.667</ci_lower_limit>
            <ci_upper_limit>29.726</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population</title>
        <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader. Duplicate scans obtained at screening and Month 12.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population</title>
          <description>Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader. Duplicate scans obtained at screening and Month 12.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.592" lower_limit="5.106" upper_limit="10.078"/>
                    <measurement group_id="O2" value="16.159" lower_limit="14.295" upper_limit="18.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and with fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.567</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.590</ci_lower_limit>
            <ci_upper_limit>11.545</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Z-score - Percent Change From Baseline to Month 36, ITT Population</title>
        <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Z-score - Percent Change From Baseline to Month 36, ITT Population</title>
          <description>Lumbar Spine Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
          <population>ITT Population</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.325" lower_limit="5.162" upper_limit="33.488"/>
                    <measurement group_id="O2" value="25.640" lower_limit="15.313" upper_limit="35.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4575</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.315</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.477</ci_lower_limit>
            <ci_upper_limit>23.107</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Z-score- Percent Change From Baseline to Month 12, ITT Population</title>
        <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population, Population Description Number of Participants Analyzed = Number of participants at baseline and LOCF data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Z-score- Percent Change From Baseline to Month 12, ITT Population</title>
          <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
          <population>ITT Population, Population Description Number of Participants Analyzed = Number of participants at baseline and LOCF data</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.661" lower_limit="-47.090" upper_limit="5.769"/>
                    <measurement group_id="O2" value="16.933" lower_limit="-1.793" upper_limit="35.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0172</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>37.594</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.801</ci_lower_limit>
            <ci_upper_limit>68.386</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Z-score- Percent Change From Baseline to Month 24, ITT Population</title>
        <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Z-score- Percent Change From Baseline to Month 24, ITT Population</title>
          <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
          <population>ITT Population</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.371" lower_limit="-22.631" upper_limit="39.373"/>
                    <measurement group_id="O2" value="7.879" lower_limit="-14.273" upper_limit="30.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9786</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.492</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.807</ci_lower_limit>
            <ci_upper_limit>35.824</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Z-score- Percent Change From Baseline to Month 36, ITT Population</title>
        <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Z-score- Percent Change From Baseline to Month 36, ITT Population</title>
          <description>Total Body Z-score - number of standard deviations a patient's BMD differs from the average BMD of their age, sex, and ethnicity. Positive scores indicate BMD above the mean; Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot;.</description>
          <population>ITT Population</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.146" lower_limit="-20.474" upper_limit="34.766"/>
                    <measurement group_id="O2" value="-1.494" lower_limit="-21.400" upper_limit="18.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5971</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.640</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.952</ci_lower_limit>
            <ci_upper_limit>23.672</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Area at Month 12, ITT Population</title>
        <description>Measured by DXA.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Area at Month 12, ITT Population</title>
          <description>Measured by DXA.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.803" lower_limit="6.751" upper_limit="10.856"/>
                    <measurement group_id="O2" value="9.817" lower_limit="8.278" upper_limit="11.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4154</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.442</ci_lower_limit>
            <ci_upper_limit>3.470</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Area at Month 24, ITT Population</title>
        <description>Measured by DXA.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Area at Month 24, ITT Population</title>
          <description>Measured by DXA.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.381" lower_limit="13.214" upper_limit="19.549"/>
                    <measurement group_id="O2" value="17.266" lower_limit="14.945" upper_limit="19.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6404</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.884</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.855</ci_lower_limit>
            <ci_upper_limit>4.623</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Area at Month 36, ITT Population</title>
        <description>Measured by DXA.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Area at Month 36, ITT Population</title>
          <description>Measured by DXA.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.952" lower_limit="20.877" upper_limit="29.027"/>
                    <measurement group_id="O2" value="23.292" lower_limit="20.296" upper_limit="26.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4978</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.660</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.499</ci_lower_limit>
            <ci_upper_limit>3.179</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body Bone Area Month 12, ITT Population</title>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body Bone Area Month 12, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.405" lower_limit="8.708" upper_limit="14.101"/>
                    <measurement group_id="O2" value="14.939" lower_limit="13.028" upper_limit="16.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0270</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.534</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.410</ci_lower_limit>
            <ci_upper_limit>6.658</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body Bone Area Month 24, ITT Population</title>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body Bone Area Month 24, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.051" lower_limit="20.684" upper_limit="27.417"/>
                    <measurement group_id="O2" value="25.116" lower_limit="22.699" upper_limit="27.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5925</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.868</ci_lower_limit>
            <ci_upper_limit>4.998</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body Bone Area Month 36, ITT Population</title>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body Bone Area Month 36, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.109" lower_limit="32.144" upper_limit="42.074"/>
                    <measurement group_id="O2" value="38.303" lower_limit="34.674" upper_limit="41.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6840</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.193</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.604</ci_lower_limit>
            <ci_upper_limit>6.991</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Morphometric Vertebral Fracture at Month 12, ITT Population</title>
        <description>Morphometric Vertebral Fracture measured by semi-quantitative (SQ) analysis of x-rays using the Genant scoring system at endpoint. (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). New fracture = SQ score is 0 at baseline and &gt;0 at the specified end visit.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>New Morphometric Vertebral Fracture at Month 12, ITT Population</title>
          <description>Morphometric Vertebral Fracture measured by semi-quantitative (SQ) analysis of x-rays using the Genant scoring system at endpoint. (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). New fracture = SQ score is 0 at baseline and &gt;0 at the specified end visit.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Least One New Fracture Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No New Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0680</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Morphometric Vertebral Fracture at Month 36, ITT Population</title>
        <description>Morphometric Vertebral Fracture measured by SQ analysis of x-rays using the Genant scoring system. (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). New fracture = SQ score is 0 at baseline and &gt;0 at the specified end visit.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>New Morphometric Vertebral Fracture at Month 36, ITT Population</title>
          <description>Morphometric Vertebral Fracture measured by SQ analysis of x-rays using the Genant scoring system. (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). New fracture = SQ score is 0 at baseline and &gt;0 at the specified end visit.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Least One New Fracture Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No New Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4121</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorization by Number of New Morphometric Vertebral Fracture at Month 12, ITT</title>
        <description>Patients with 1 or more New Morphometric Vertebral Fracture as measured by SQ analysis of x-rays using the Genant scoring system (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). Incidence = SQ score is 0 at baseline and &gt;0 at post-baseline.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Categorization by Number of New Morphometric Vertebral Fracture at Month 12, ITT</title>
          <description>Patients with 1 or more New Morphometric Vertebral Fracture as measured by SQ analysis of x-rays using the Genant scoring system (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). Incidence = SQ score is 0 at baseline and &gt;0 at post-baseline.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No New Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three or more Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3658</p_value>
            <method>Savage Exact Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorization by Number of New Morphometric Vertebral Fracture at Month 36, ITT</title>
        <description>Patients with 1 or more New Morphometric Vertebral Fracture as measured by SQ analysis of x-rays using the Genant scoring system (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). Incidence = SQ score is 0 at baseline and &gt;0 at post-baseline.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Categorization by Number of New Morphometric Vertebral Fracture at Month 36, ITT</title>
          <description>Patients with 1 or more New Morphometric Vertebral Fracture as measured by SQ analysis of x-rays using the Genant scoring system (Ref: Genant 1993). SQ-Scores range from 0 (no fracture) to 3 (severe fracture). Incidence = SQ score is 0 at baseline and &gt;0 at post-baseline.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No New Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three or more Fractured Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3408</p_value>
            <method>Savage Exact Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence New Vertebral Fractures by SQ (Semi-Quantitative) Score, Patients Aged 4-9 Years, Month 12, ITT Population</title>
        <description>Patients aged 4-9 years with new morphometric vertebral fractures as measured by SQ analysis of x-rays using the Genant scoring system at Month 12 +/- 14 days. (Ref: Genant 1993). SQ Score mild - 0/no fracture to Grade 1, Moderate to Severe - change from 0/no fracture to Grade 2-3.</description>
        <time_frame>Month 12</time_frame>
        <population>ITT Population, Number of Participants Analyzed = Number of participants with baseline and Month 12 data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence New Vertebral Fractures by SQ (Semi-Quantitative) Score, Patients Aged 4-9 Years, Month 12, ITT Population</title>
          <description>Patients aged 4-9 years with new morphometric vertebral fractures as measured by SQ analysis of x-rays using the Genant scoring system at Month 12 +/- 14 days. (Ref: Genant 1993). SQ Score mild - 0/no fracture to Grade 1, Moderate to Severe - change from 0/no fracture to Grade 2-3.</description>
          <population>ITT Population, Number of Participants Analyzed = Number of participants with baseline and Month 12 data</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number Patients with New Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of New Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients New Fractures &amp; Mild SQ Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients New Fractures &amp; Mod/Sev SQ Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence New Vertebral Fractures by SQ Score, Patients Aged 10-15 Years, Month 12, ITT Population</title>
        <description>Patients aged 10-15 years with new morphometric vertebral fractures as measured by SQ analysis of x-rays using the Genant scoring system at Month 12 +/- 14 days. (Ref: Genant 1993). SQ Score mild - 0/no fracture to Grade 1, Moderate to Severe - change from 0/no fracture to Grade 2-3.</description>
        <time_frame>Month 12</time_frame>
        <population>ITT Population, Number of Participants Analyzed = Number of participants at baseline and Month 12 data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence New Vertebral Fractures by SQ Score, Patients Aged 10-15 Years, Month 12, ITT Population</title>
          <description>Patients aged 10-15 years with new morphometric vertebral fractures as measured by SQ analysis of x-rays using the Genant scoring system at Month 12 +/- 14 days. (Ref: Genant 1993). SQ Score mild - 0/no fracture to Grade 1, Moderate to Severe - change from 0/no fracture to Grade 2-3.</description>
          <population>ITT Population, Number of Participants Analyzed = Number of participants at baseline and Month 12 data</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number Patients with New Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of New Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients New Fractures &amp; Mild SQ Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients New Fractures &amp; Mod/Sev SQ Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probability of Fracture in 12 Months (Kaplan-Meier Cumulative Incidence), ITT Population</title>
        <description>Long bones include radius, ulna, humerus, tibia, fibula, femur, upper limb and lower limb fracture.</description>
        <time_frame>Time to First Event (days) up to 12 Months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of Fracture in 12 Months (Kaplan-Meier Cumulative Incidence), ITT Population</title>
          <description>Long bones include radius, ulna, humerus, tibia, fibula, femur, upper limb and lower limb fracture.</description>
          <population>ITT Population</population>
          <units>Probability of Fractures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number Patients All Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="29"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Fractures/Kaplan-Meier Cumulative Incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5043" spread=".0740"/>
                    <measurement group_id="O2" value="0.314" spread=".0484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vertebral Fractures/Kaplan-Meier Cumulative Incid.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Vertebral Fractures/Kaplan-Meier Cum. Incid.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5043" spread="0.0740"/>
                    <measurement group_id="O2" value="0.314" spread="0.0484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients Long Bone Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long Bone Non-Vertebral Fractures/Kaplan-Meier Cum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3618" spread="0.0714"/>
                    <measurement group_id="O2" value="0.1954" spread="0.0413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients Other Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Non-Vertebral Fractures/Kaplan-Meier Cum.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.204" spread="0.0576"/>
                    <measurement group_id="O2" value="0.1311" spread="0.0353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0253</p_value>
            <p_value_desc>All Fractures</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Hazard Ratio and 95% CI based on Cox proportional hazards model stratified by age group with treatment and pooled-country as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.534</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.310</ci_lower_limit>
            <ci_upper_limit>0.922</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0253</p_value>
            <p_value_desc>All Non-Vertebral Fractures</p_value_desc>
            <method>Cox Proportional Hazard</method>
            <method_desc>Hazard Ratio and 95% CI based on Cox proportional hazards model stratified by age group with treatment and pooled-country as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.534</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.310</ci_lower_limit>
            <ci_upper_limit>0.922</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0501</p_value>
            <p_value_desc>Long Bone Non-Vertebral Fracture</p_value_desc>
            <method>Cox Proportional Hazards</method>
            <method_desc>Hazard Ratio and 95% CI based on Cox proportional hazards model stratified by age group with treatment and pooled-country as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.487</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.250</ci_lower_limit>
            <ci_upper_limit>0.950</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2141</p_value>
            <p_value_desc>Other Non-Vertebral Fracture</p_value_desc>
            <method>Cox Proportional Hazard</method>
            <method_desc>Hazard Ratio and 95% CI based on Cox proportional hazards model stratified by age group with treatment and pooled-country as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.608</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.262</ci_lower_limit>
            <ci_upper_limit>1.410</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinical Fractures, Month 12, ITT Population</title>
        <description>Long bones include radius, ulna, humerus, tibia, fibula, femur, upper limb and lower limb fracture.</description>
        <time_frame>12 Months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinical Fractures, Month 12, ITT Population</title>
          <description>Long bones include radius, ulna, humerus, tibia, fibula, femur, upper limb and lower limb fracture.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Patients with Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients with Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients with Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Long-Bone Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients Long-Bone Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Other Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Patients with Other Non-Vertebral Fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0416</p_value>
            <p_value_desc>All Fractures</p_value_desc>
            <method>Wald test</method>
            <method_desc>Hazard Ratio and 95% CI based on Anderson-Gill mean intensity model stratified by age group with treatment and pooled-country as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.584</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.348</ci_lower_limit>
            <ci_upper_limit>0.980</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0416</p_value>
            <p_value_desc>Non-Vertebral Fracture</p_value_desc>
            <method>Wald Test</method>
            <method_desc>Hazard Ratio and 95% CI based on Anderson-Gill mean intensity model stratified by age group with treatment and pooled-country as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.584</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.348</ci_lower_limit>
            <ci_upper_limit>0.980</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0799</p_value>
            <p_value_desc>Long Bone Non-Vertebral Fracture</p_value_desc>
            <method>Wald Test</method>
            <method_desc>Hazard Ratio and 95% CI based on Anderson-Gill mean intensity model stratified by age group with treatment and pooled-country as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.543</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.274</ci_lower_limit>
            <ci_upper_limit>1.076</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.682</p_value>
            <p_value_desc>Other Non-Vertebral Fracture</p_value_desc>
            <method>Wald Test</method>
            <method_desc>Hazard Ratio and 95% CI based on Anderson-Gill mean intensity model stratified by age group with treatment and pooled-country as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.682</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.304</ci_lower_limit>
            <ci_upper_limit>1.532</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum BAP - Percent Change From Baseline to Month 12, ITT Population</title>
        <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
        <time_frame>Baseline and 12 Months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum BAP - Percent Change From Baseline to Month 12, ITT Population</title>
          <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.783" lower_limit="-2.107" upper_limit="15.674"/>
                    <measurement group_id="O2" value="-4.895" lower_limit="-11.509" upper_limit="1.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0318</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.678</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.325</ci_lower_limit>
            <ci_upper_limit>-1.031</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum BAP - Percent Change From Baseline to Month 24, ITT Population</title>
        <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
        <time_frame>Baseline and 24 Months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum BAP - Percent Change From Baseline to Month 24, ITT Population</title>
          <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.196" lower_limit="-20.748" upper_limit="-1.643"/>
                    <measurement group_id="O2" value="-11.128" lower_limit="-18.286" upper_limit="-3.971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9907</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.401</ci_lower_limit>
            <ci_upper_limit>11.536</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum BAP - Percent Change From Baseline to Month 36, ITT Population</title>
        <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
        <time_frame>Baseline and 36 Months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum BAP - Percent Change From Baseline to Month 36, ITT Population</title>
          <description>Serum Bone Alkaline Phosphatase (BAP - bone formation marker). Negative percent changes indicate response to treatment.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.884" lower_limit="-28.658" upper_limit="-11.109"/>
                    <measurement group_id="O2" value="-24.570" lower_limit="-31.304" upper_limit="-17.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3826</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.686</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.276</ci_lower_limit>
            <ci_upper_limit>5.903</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine NTX/Cr - Percent Change From Baseline at Month 12, ITT Population</title>
        <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
        <time_frame>Baseline and Endpoint / Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Urine NTX/Cr - Percent Change From Baseline at Month 12, ITT Population</title>
          <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.556" lower_limit="-24.218" upper_limit="-4.894"/>
                    <measurement group_id="O2" value="-41.185" lower_limit="-48.625" upper_limit="-33.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-26.629</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-38.089</ci_lower_limit>
            <ci_upper_limit>-15.169</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine NTX/Cr - Percent Change From Baseline at Month 24, ITT Population</title>
        <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Urine NTX/Cr - Percent Change From Baseline at Month 24, ITT Population</title>
          <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.358" lower_limit="-54.722" upper_limit="-25.994"/>
                    <measurement group_id="O2" value="-31.318" lower_limit="-42.478" upper_limit="-20.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3075</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.433</ci_lower_limit>
            <ci_upper_limit>26.512</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine NTX/Cr - Percent Change From Baseline at Month 36, ITT Population</title>
        <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Urine NTX/Cr - Percent Change From Baseline at Month 36, ITT Population</title>
          <description>Urine type-I collagen N-telopeptide/creatinine (NTX/Cr; bone resorption marker). Negative percent changes indicate response to treatment.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.570" lower_limit="-57.317" upper_limit="-37.823"/>
                    <measurement group_id="O2" value="-52.609" lower_limit="-60.203" upper_limit="-45.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3998</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.849</ci_lower_limit>
            <ci_upper_limit>6.772</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wong-Baker FACES Pain Rating Scale - Change From Baseline to Month 12, ITT Population</title>
        <description>Wong-Baker FACES Pain Rating Scale (pain assessment scale using facial expressions, translated into a range from 0= no pain [smiling face] to 10= worst pain possible [distorted face with tears]; negative values indicate decrease in pain). Reference: Wong DL et al.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Wong-Baker FACES Pain Rating Scale - Change From Baseline to Month 12, ITT Population</title>
          <description>Wong-Baker FACES Pain Rating Scale (pain assessment scale using facial expressions, translated into a range from 0= no pain [smiling face] to 10= worst pain possible [distorted face with tears]; negative values indicate decrease in pain). Reference: Wong DL et al.</description>
          <population>ITT Population</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" lower_limit="-0.471" upper_limit="0.358"/>
                    <measurement group_id="O2" value="-0.409" lower_limit="-0.712" upper_limit="-0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1592</p_value>
            <method>ANCOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.352</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.845</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Age (Years), Change From Baseline to Month 12, ITT Population</title>
        <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Age (Years), Change From Baseline to Month 12, ITT Population</title>
          <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
          <population>ITT Population</population>
          <units>Years</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.956" lower_limit="0.756" upper_limit="1.155"/>
                    <measurement group_id="O2" value="1.083" lower_limit="0.935" upper_limit="1.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2917</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and p-value are from ANOVA model with fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.127</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.111</ci_lower_limit>
            <ci_upper_limit>0.365</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Age (Years), Change From Baseline to Month 24, ITT Population</title>
        <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Age (Years), Change From Baseline to Month 24, ITT Population</title>
          <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
          <population>ITT Population</population>
          <units>Years</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.147" lower_limit="1.888" upper_limit="2.407"/>
                    <measurement group_id="O2" value="2.155" lower_limit="1.962" upper_limit="2.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9622</p_value>
            <method>ANOVA</method>
            <method_desc>LS mean and p-value are from ANOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.007</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.304</ci_lower_limit>
            <ci_upper_limit>0.319</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Age (Years), Change From Baseline to Month 36, ITT Population</title>
        <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Age (Years), Change From Baseline to Month 36, ITT Population</title>
          <description>Bone Age determined by visual assessment of hand / wrist radiographs.</description>
          <population>ITT Population</population>
          <units>Years</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.087" lower_limit="2.800" upper_limit="3.374"/>
                    <measurement group_id="O2" value="3.096" lower_limit="2.879" upper_limit="3.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9596</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and p-value are from ANOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.336</ci_lower_limit>
            <ci_upper_limit>0.354</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Growth Velocity - Change From Baseline to Month 12, ITT Population</title>
        <description>Annualized Growth Velocity [= bone age change from baseline x (365.25/time in days between baseline and the bone age measurement)]</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>ITT Population, Number of Participants Analyzed = Number of participants at baseline and Month 12 data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Growth Velocity - Change From Baseline to Month 12, ITT Population</title>
          <description>Annualized Growth Velocity [= bone age change from baseline x (365.25/time in days between baseline and the bone age measurement)]</description>
          <population>ITT Population, Number of Participants Analyzed = Number of participants at baseline and Month 12 data</population>
          <units>Change in Annualized Growth Velocity</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.895" lower_limit="0.709" upper_limit="1.080"/>
                    <measurement group_id="O2" value="1.002" lower_limit="0.865" upper_limit="1.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3400</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and p-value are from ANOVA model with fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.107</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.114</ci_lower_limit>
            <ci_upper_limit>0.328</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Growth Velocity - Change From Baseline to Month 36, ITT Population</title>
        <description>Annualized Growth Velocity [= bone age change from baseline x (365.25/time in days between baseline and the bone age measurement)]</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>ITT Population, Number of Participants Analyzed = Number of participants at baseline and Month 12 data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Daily</title>
            <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
          </group>
          <group group_id="O2">
            <title>Risedronate Daily</title>
            <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Growth Velocity - Change From Baseline to Month 36, ITT Population</title>
          <description>Annualized Growth Velocity [= bone age change from baseline x (365.25/time in days between baseline and the bone age measurement)]</description>
          <population>ITT Population, Number of Participants Analyzed = Number of participants at baseline and Month 12 data</population>
          <units>Change in Annualized Growth Velocity</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.982" lower_limit="0.886" upper_limit="1.077"/>
                    <measurement group_id="O2" value="1.011" lower_limit="0.941" upper_limit="1.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A total of 123 patients were to be randomized in 2:1 ratio. The sample size allowed detection of a difference of at least 5% in lumbar spine BMD percent change from baseline to 12 months with 90% power. Calculation based on assumption that common within-group SD would be approximately 7% and dropout rate within Year 1 would be 20%. A difference of 5% in lumbar spin BMD percent change from baseline was considered clinically meaningful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6218</p_value>
            <method>ANOVA</method>
            <method_desc>LS means and p-value are from ANCOVA model adjusted by baseline and fixed effects for age group, treatment and pooled center for post-baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.084</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months: One year double-blind treatment, 2 years open-label risedronate treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Daily</title>
          <description>placebo tablet, once a day for one year then for two years open label risedronate</description>
        </group>
        <group group_id="E2">
          <title>Risedronate Daily</title>
          <description>risedronate tablet, once a day for one year then for two years open label risedronate once a day</description>
        </group>
        <group group_id="E3">
          <title>Years 2 &amp; 3 Placebo-Risedronate</title>
          <description>Year 1 Placebo Double-Blind, Years 2 &amp; 3 Open-Label Risedronate</description>
        </group>
        <group group_id="E4">
          <title>Years 2 &amp; 3 Risedronate</title>
          <description>Years 1-3 Risedronate, Double-Blind Year 1, Open-Label Years 2 &amp; 3</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic Membrane Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Ilium Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Bone Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="28" subjects_affected="14" subjects_at_risk="94"/>
                <counts group_id="E3" events="13" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="12" subjects_affected="5" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="13" subjects_affected="8" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E3" events="10" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="16" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="21" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="94"/>
                <counts group_id="E3" events="31" subjects_affected="22" subjects_at_risk="49"/>
                <counts group_id="E4" events="55" subjects_affected="36" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E4" events="17" subjects_affected="12" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="94"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="23" subjects_affected="11" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="94"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="20" subjects_affected="13" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E4" events="11" subjects_affected="5" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="94"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="13" subjects_affected="8" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="18" subjects_affected="8" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="7" subjects_affected="2" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" events="14" subjects_affected="12" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The findings of the study may be published in a scientific journal or presented at a scientific meeting. Before submitting the results of the study for publication or presentation, the Investigator will allow the Sponsor 30 days in which to review and comment on the manuscript.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The clinical meaningfulness of new fractures in the thoracic spine scored as Genant Grade I is unclear, thus the morphometric vertebral fracture data are evaluated further.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Grexan Wulff, Manager Regulatory Affairs</name_or_title>
      <organization>Warner Chilcott</organization>
      <phone>973-442-3376</phone>
      <email>gwulff@wcrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

